Randomized Trial of a GPIIb/IIIa Platelet Receptor Blocker in Refractory Unstable Angina

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Circulation

• Publication date

  1994-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.89.2.596PMID 7508826
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.

  1993cited by this paper
• Thrombolysis in Patients With Unstable Angina Improves the Angiographic but Not the Clinical Outcome: Results of UNASEM, A Multicenter, Randomized, Placebo‐Controlled, Clinical Trial With Anistreplase

  1992cited by this paper
• Tissue plasminogen activator in refractory unstable angina. A randomized double-blind placebo-controlled trial in patients with refractory unstable angina and subsequent angioplasty.

  1991cited by this paper
• Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden.

  1991cited by this paper
• Thrombolysis in myocardial Infarction (TIMI) trial–phase I

  1990cited by this paper
• Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial.

  1990cited by this paper
• Unstable angina and coronary angioplasty.

  1990cited by this paper
• Dynamic QRS and ST-segment changes in myocardial infarction monitored by continuous on-line vectorcardiography.

  1990cited by this paper
• Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.

  1990cited by this paper
• Unstable angina. A classification.

  1989cited by this paper
• Intracoronary thrombus and complex morphology in unstable angina. Relation to timing of angiography and in-hospital cardiac events.

  1989cited by this paper
• Unstable Angina A Classification

  1989cited by this paper
• Randomized, double-blind, placebo-controlled trial of tissue plasminogen activator in unstable angina.

  1989cited by this paper
• Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes.

  1989cited by this paper
• Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.

  1988cited by this paper
• Effects of thrombolytic therapy in unstable angina: clinical and angiographic results.

  1988cited by this paper
• Aspirin, heparin, or both to treat acute unstable angina.

  1988cited by this paper
• Insights into the pathogenesis of acute ischemic syndromes.

  1988cited by this paper
• Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase*

  1987cited by this paper
• Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy.

  1987cited by this paper
• Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

  1987cited by this paper
• Coronary angioplasty early after diagnosis of unstable angina.

  1987cited by this paper
• A perspective of coronary disease seen through the arteries of living man.

  1987cited by this paper
• Activation affects access to the platelet receptor for adhesive glycoproteins

  1986cited by this paper
• Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Report of The Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group.

  1986cited by this paper
• Frequency of intracoronary filling defects by angiography in angina pectoris at rest.

  1985cited by this paper
• Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms.

  1985cited by this paper
• Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor.

  1985cited by this paper
• Determinants of risk for coronary artery bypass grafting in stable and unstable angina pectoris.

  1985cited by this paper
• Acute coronary events associated with percutaneous transluminal coronary angioplasty.

  1984cited by this paper
• Assessment of percutaneous transluminal coronary angioplasty by quantitative coronary angiography: diameter versus densitometric area measurements.

  1984cited by this paper
• Computer densitometry for angiographic assessment of arterial cholesterol content and gross pathology in human atherosclerosis.

  1977cited by this paper
• Unstable angina pectoris: morbidity and mortality in 57 consecutive patients evaluated angiographically.

  1973cited by this paper

• Some Group Sequential Trials from Industry over the Last 30 Years

  2024cites this paper
• Current innovative engineered antibodies.

  2022cites this paper
• Clinical pharmacology of antiplatelet drugs

  2022cites this paper
• A Novel Antibody Targeting the Second Extracellular Loop of the Serotonin 5-HT2A Receptor Inhibits Platelet Function

  2022cites this paper
• Delayed thrombocytopenia following administration of abciximab: Pharmacovigilance survey and literature review.

  2021cites this paper
• Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review.

  2019cites this paper
• Multicentre Study of the P 2 T Receptor Antagonist AR-C 69931 MX Assessing Safety , Tolerability and Activity in Patients with Acute Coronary Syndromes

  2018cites this paper
• Anti-Atherosclerotic Properties of Antihypertensive Drugs: Effect of Antihypertensive Therapy on Platelet Receptors for von Willebrand Factor and for Fibrinogen

  2016cites this paper
• How abciximab might be clinically useful.

  2016cites this paper
• Risk Factors Associations Between a Polymorphism in the Gene Encoding Glycoprotein IIIa and Myocardial Infarction or Coronary Artery Disease

  2016cites this paper
• Efficacy and safety of tirofiban in patients with non-ST segment elevation acute coronary syndromes : a systemic review and meta-analysis

  2016cites this paper
• Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.

  2013cites this paper
• Role of Parenteral Agents in Percutaneous Coronary Intervention for Stable Patients.

  2013cites this paper
• Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.

  2013cites this paper
• Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention

  2013cites this paper
• GP IIb/IIIa inhibitors for STEMI: still the gold standard or an old survivor?

  2012cites this paper
• Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions

  2011cites this paper
• Improved Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) of Affinity Maturated and Fc-Engineered Antibodies Directed Against the AML Stem Cell Antigen CD96

  2011cites this paper
• Textbook of interventional neurology

  2011cites this paper
• Textbook of Interventional Neurology: Pathophysiological and pharmacological treatment of thromboembolic and ischemic complications associated with endovascular procedures

  2011cites this paper
• Propiedades de los diferentes inhibidores de la glucoproteína IIb/IIIa: ¿se puede aceptar el efecto de clase?

  2011cites this paper
• Adult Cardiac Anesthesia

  2010cites this paper
• Correlation of Inhibition of Platelet Aggregation With Cardiovascular and Bleeding Outcomes in Acute Coronary Syndromes

  2010cites this paper
• Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.

  2010cites this paper
• Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective.

  2010cites this paper
• ST-segment Elevation Myocardial Infarction in a Patient with Polycythemia Vera Managed with High-dose Tirofiban Pre-treatment, Aspiration Thrombectomy, and Paclitaxel-eluting Stent Implantation

  2010cites this paper
• A Multicenter, Randomized, Open-Label, Therapeutic, and Exploratory Trial to Evaluate the Tolerability and Efficacy of Platelet Glycoprotein IIb/IIIa Receptor Blocker (Clotinab™) in High-Risk Patients with Percutaneous Coronary Intervention

  2008cites this paper
• The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

  2008cites this paper
• Human Monoclonal Antibodies from Transgenic Mice

  2008cites this paper
• Large thrombus burden, slow-flow, no-reflow and distal embolization

  2007cites this paper
• Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.

  2007cites this paper
• Rationale for intracoronary administration of abciximab

  2007cites this paper
• THE GPIIB/IIIA ANTAGONIST ABCIXIMAB FOR ACUTE PERCUTANEOUS CORONARY INTERVENTION

  2007cites this paper
• Target validation in drug discovery.

  2007cites this paper
• Clinical policy: critical issues in the evaluation and management of adult patients with non-ST-segment elevation acute coronary syndromes.

  2006cites this paper
• Pathogenesis of Atherosclerosis

  2006cites this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: A report of the American college of cardiology/American heart association task force on practice guidelines(ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention)

  2006cites this paper
• Le point sur les anticorps autorisés en imagerie et en immunothérapie

  2006cites this paper
• Risk Stratification and Risk Modification in Patients with Acute Coronary Syndromes

  2006cites this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention).

  2006cites this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).

  2006cites this paper
• Clotting for the clinician: An overview of thrombosis and antithrombotic therapy

  2005cites this paper
• Glycoprotein IIb/IIIa antagonists: a systematic review of randomized clinical trials in patients undergoing percutaneous coronary intervention

  2005cites this paper
• Assessing Platelet Function in Clinical Trials

  2005cites this paper
• Gli antagonisti del recettore GPIIb/IIIa: farmacologia, clinica ed economia nelle sindromi coronariche acute NSTEMI e nelle rivascolarizzazioni per via percutanea

  2005cites this paper
• Key references: Antiplatelet therapy as an adjunct to thrombolysis and coronary angioplasty

  2005cites this paper
• Bedside Platelet Monitoring

  2004cites this paper
• Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art

  2004cites this paper
• Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug

  2004cites this paper
• Enhancing thrombolysis with adjunctive therapy

  2004cites this paper
• Comparative Pharmacodynamic Evaluation of Eptifibatide and Abciximab in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: The TAM2 Study

  2004influential citation
• Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.

  2004cites this paper
• Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.

  2003cites this paper
• Pharmacotherapeutic considerations in anesthesia.

  2003cites this paper
• Controversies surrounding the use of glycoprotein IIb/IIIa inhibitors.

  2003cites this paper
• Suboptimal Inhibition of Platelet Aggregation Following Tirofiban Bolus in Patients Undergoing Percutaneous Coronary Intervention for Unstable Angina Pectoris

  2003cites this paper
• A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers.

  2003cites this paper
• Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris.

  2003cites this paper
• Glycoprotein IIb/IIIa Antagonists

  2003cites this paper
• Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban

  2003cites this paper
• Acute ischemic syndromes. Adjunctive therapy.

  2002cites this paper
• Variability in abciximab (ReoPro®) prescribing: evidence based or budget driven?

  2002cites this paper
• The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.

  2002cites this paper
• Platelets and Cardiovascular Disease

  2002cites this paper
• Monitoring of platelet function in the setting of glycoprotein IIb/IIIa inhibitor therapy.

  2002cites this paper
• Drugs in development.

  2002cites this paper
• Stent-Based Local Pharmacotherapy: Abciximab

  2002cites this paper
• Coronary Circulation and Myocardial Ischaemia: Thrombolysis

  2002cites this paper
• Early use of glycoprotein IIb/IIIa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes.

  2002cites this paper
• The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors.

  2002cites this paper
• Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban

  2001cites this paper
• Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.

  2001cites this paper
• The P2Y 12 receptor as a therapeutic target in cardiovascular disease

  2001cites this paper
• Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes: Gusto IV-ACS.

  2001cites this paper
• Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.

  2001cites this paper
• Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes

  2001cites this paper
• Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.

  2001cites this paper
• Risk Stratification in Non‐ST Segment Elevation Acute Coronary Syndromes with Special Focus on Recent Guidelines

  2001cites this paper
• Clinical experience with antithrombotic drugs acting on purine receptor pathways

  2001cites this paper
• Respuesta variable a la inhibición biológica de las plaquetas por abciximab en pacientes sometidos a revascularización coronaria percutánea

  2001cites this paper
• [Variable response to the biological inhibition of platelets by abciximab in patients subjected to percutaneous coronary angioplasty].

  2001cites this paper
• Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study

  2001cites this paper
• Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention

  2001cites this paper
• Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes

  2001cites this paper
• Evaluation of local abciximab delivery from the surface of a polymer-coated covered stent: in vivo canine studies.

  2001cites this paper
• Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.

  2001cites this paper
• Bleeding in a Patient Receiving Platelet Aggregation Inhibitors

  2001cites this paper
• Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention.

  2001cites this paper
• High Platelet Count in Platelet-Rich Plasma Reduces Measured Platelet Inhibition by Abciximab but not Tirofiban nor Eptifibatide Glycoprotein IIb/IIIa Receptor Antagonists

  2000cites this paper
• Use of the PFA-100™ Apparatus to Assess Platelet Function in Patients Undergoing PTCA during and after Infusion of cE3 Fab in the Presence of other Antiplatelet Agents

  2000cites this paper
• Applications of Anti-Platelet Monitoring in Catheterization Laboratory

  2000cites this paper
• [The efficacy of platelet IIb/IIIa receptor blockers in acute coronary syndromes].

  2000cites this paper
• Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961

  2000cites this paper
• Effect of acupuncture on monoamines and adenosine triphosphatase activity in lateral hypothaiamic area of obese rats

  2000cites this paper
• Antagonistas do receptor plaquetário GPIIb/IIIa

  2000cites this paper
• Platelet glycoprotein IIIa PlA1/A2 polymorphism and its relationship with diabetic nephropathy in type 2 diabetic patients.

  2000cites this paper
• Potential Role of Platelet Glycoprotein IIb/IIIa Antagonists in Cerebrovascular Disorders

  2000cites this paper
• Antiplatelet Effects of MK‐852, a Platelet Fibrinogen Receptor Antagonist, in Healthy Volunteers

  2000cites this paper
• Monitoring Antiplatelet Therapy

  2000cites this paper
• Effect of xuefu zhuyu decoction on the function of platelets and human umbilical vein endothelial cell

  2000cites this paper